News
GNPX
--
0.00%
--
Genprex to Participate in a Monthly CEO Roadshow Webinar Series
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Var...
Business Wire · 07/20 12:30
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15)
Benzinga · 07/16 11:37
Genprex Shares Rise 8% on FDA Review of Reqorsa Trial
marketwatch.com · 06/23 14:42
BRIEF-Genprex Announces Initiation Of Its Phase 1/2 Acclaim-1 Clinical Trial For REQORSA Immunogene Therapy
reuters.com · 06/23 13:11
Genprex initiates early-stage REQORSA lung cancer study
Genprex (GNPX) announces initiation of the company's phase 1/2 Acclaim-1 clinical trial for REQORSA immunogene therapy in combination with Tagrisso to treat non-small cell lung cancer following U.S. FDA review.The company
Seekingalpha · 06/23 12:44
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA(TM) Immunogene Therapy in Combination with Tagrisso(R) to Treat Non-Small Cell Lung Cancer Following FDA Review
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the U.S. Food and Drug Administration (FDA) has revie...
Business Wire · 06/23 12:30
Is Genprex, Inc. (GNPX) A Good Stock To Buy Now?
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money invest...
Insider Monkey · 06/22 23:08
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 06/18 12:19
Companies Like Genprex (NASDAQ:GNPX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 06/11 07:32
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
Genprex's President and CEO will present at Noble Capital Markets’ Virtual Roadshow Series on Thursday, May 20 at 1 pm ET
Business Wire · 05/19 12:30
From BZ Small Cap Event: Wrap Technologies CEO Tom Smith Now Speaking Live
https://www.youtube.com/watch?v=Jrcq_ymSBt0
Benzinga · 05/14 15:36
Schedule For Benzinga's Global Small Cap Conference Thursday, May 13, 2021
Check out the full agenda via Benzinga's Events page: https://www.benzinga.com/events/small-cap/global/#agenda * the list below is limited to some of the publicly-traded companies that will be presenting
Check out the full agenda via Benzinga's Events page:  * the list below is limited to some of the publicly-traded companies that will be presenting · 05/13 13:08
Benzinga Pro's Top 6 Stocks To Watch For Thursday, May 13, 2021 (BZ Small Cap Event Edition): UGRO, CANF, MYMD, OBLG, ELYS, GNPX
Today's 5 Stock Ideas (BZ Small Cap Event Edition) Benzinga is hosting another of it's famed Benzinga Global Small Cap Conferences this week!  The festivities kick off Thursday morning just after 9 a.m.
Benzinga · 05/13 12:25
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences
May 10, 2021 (Investor Brand Network via COMTEX) -- Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing...
Investor Brand Network · 05/10 16:25
Genprex to Participate in Upcoming May Investor Conferences
Genprex will participate in conferences throughout May 2021.
Business Wire · 05/10 12:30
BioMedNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Announces Expansion of World-Class IP Portfolio
May 06, 2021 (Investor Brand Network via COMTEX) -- Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing...
Investor Brand Network · 05/06 19:05
BRIEF-Genprex In-Licenses Additional Gene Therapy Technologies For Treatment Of Lung Cancer
reuters.com · 05/06 13:37
Diamond Equity Research Emerging Growth Invitational Spring 2021 Virtual Conference
Our conferences are open to both institutional and retail investors, allowing all investors to obtain meaningful access to management teams" stated Hunter Diamond, CFA the CEO of Diamond Equity Research.Investors can register at https://www.
ACCESSWIRE · 05/06 13:31
Genprex in-licenses additional gene therapy technologies for treatment of lung cancer
Genprex ([[GNPX]] +2.5%) announces that it has in-licensed additional gene therapy technologies for the treatment of lung cancer.The company and a major cancer research center in Houston, Texas has entered into an amendment to
Seekingalpha · 05/06 13:31
Genprex Secures Additional Gene Therapy Technologies for Lung Cancer Treatment
MT Newswires · 05/06 13:14
Webull provides a variety of real-time GNPX stock news. You can receive the latest news about Genprex Inc through multiple platforms. This information may help you make smarter investment decisions.
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on developing cancer-based upon its novel technology platform, including its initial product candidate, Oncoprex, immunogene therapy, or Oncoprex. Oncoprex consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects and is thereby considered an immunogene therapy. The gene is one of a series of genes whose therapeutic use is covered by a license from The University of Texas MD Anderson Cancer Center (MD Anderson). It is also developing a pre-clinical gene therapy that is covered by a license from the University of Pittsburgh of the Commonwealth System of Higher Education that has the potential to cure type 1 and type 2 diabetes. It is developing its product candidate to be administered with targeted therapies and with immunotherapies for non-small cell lung cancer (NSCLC).